^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T).

Published date:
02/06/2020
Excerpt:
The majority of PFS events occurred in the TMB-low/TI-GEP-low subgroup.
Trial ID: